Navigation Links
Live Press Briefing on Findings of Biomedical Industry CEO Survey
Date:1/9/2012

SAN FRANCISCO, Jan. 9, 2012 EVENT:Live Press Briefing on Findings of Biomedical Industry CEO SurveyWHEN:Tuesday, Jan. 10, 2012 TIME:10 a.m. – 10:45 a.m. PT presentation and Q&A 

 WHO:-- CEOs from three biotechnology companies: NuVasive (NASDAQ: NUVA), Omniox and Theravance (NASDAQ: THRX) 

-- Executives from BayBio, California Healthcare Institute and PwC USWHERE:Grand Hyatt San Francisco 

Conference Theatre 

345 Stockton St. 

San Francisco, CA 94108  

To listen by phone in the United States: (800) 230-1951 (Logo: http://photos.prnewswire.com/prnh/20100917/NY66894LOGO )

Findings of a new survey of biomedical company CEOs about the future of the biomedical industry will be unveiled at a live press briefing hosted by the California Healthcare Institute, BayBio and PwC in San Francisco on Tuesday, Jan. 10. Some of the questions that will be addressed during the briefing include:

  • What are the biggest threats to future growth of the biomedical industry?
  • How are biomedical companies adapting to new threats and opportunities?
  • Where are biomedical companies turning for capital, and who will finance new innovation in the future?
  • How does the relationship between industry and FDA help or hinder innovation?
  • What are the key state and federal policy issues that will influence the ability for the United States and California to maintain global leadership in biomedical innovation?
  • While the biomedical industry may be poised for explosive growth over the next five to 10 years, the pace will be determined by a confluence of factors — the political, economic and regulatory environment, the availability of capital, health reform, globalization and state and federal budget deficits. These factors and the relative risks and opportunities they represent to the biomedical industry are among the topics explored by the survey.

    The briefing will include a presentation of research highlights, followed by a candid discussion among the CEOs of three California-based biomedical companies. The briefing will allow time at the conclusion for questions from the audience and members of the media.

  • NuVasive, Alexis Lukianov, Chairman and CEO
  • Omniox, Stephen Cary, Ph.D., CEO and Co-Founder
  • Theravance, Rick Winningham, Chairman and CEO
  • BayBio, Gail Maderis, President and CEO
  • California Healthcare Institute, David Gollaher, Ph.D., President and CEO
  • PwC, Tracy Lefteroff, National Life Sciences Partner
  • About the California Healthcare Institute
    CHI represents more than 275 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI's mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI's website is www.chi.org. Follow us on Twitter @calhealthcare, Facebook, LinkedIn and YouTube.

    About BayBio
    BayBio is Northern California's life science association, supporting the regional bioscience community through advocacy, enterprise support, and the enhancement of research collaboration. Its members include organizations engaged in, or supportive of, research, development and commercialization of life science technologies. Online at www.baybio.org.Follow BayBio on Twitter at @baybio

    About the PwC Network
    PwC firms help organizations and individuals create the value they're looking for. We're a network of firms in 158 countries with close to 169,000 people who are committed to delivering quality in assurance, tax and advisory services. Tell us what matters to you and find out more by visiting us at www.pwc.com.
    © 2011 PricewaterhouseCoopers LLP, a Delaware limited liability partnership. All rights reserved. PwC refers to the US member firm, and may sometimes refer to the PwC network. Each member firm is a separate legal entity. Please see www.pwc.com/structure for further details.

     

     

     


    '/>"/>
    SOURCE PwC
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis
    2. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
    3. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
    4. Compressus Drives Programmable Workflow And Unprecedented Flexibility With Introduction of MEDxConnect™ v4.0
    5. Nations Best Health Care Organizations for Patient Satisfaction, Core Measures Honored by Press Ganey
    6. Bright Light into the Ear Canal Treats Seasonal Depression Effectively in Two Clinical Trials Presented by Valkee and University of Oulu
    7. Epitomics, Inc. Receives Notice of Allowance from the United States Patent and Trademark Office for a Novel Method for Identifying Differentially Expressed Proteins
    8. Drug-Free BLOOD PRESSURE Control & Medical "Take-Away" Treatment are Potential Win-Win Solutions in Health Care
    9. Optics Express Focus Issue: Collective phenomena in photonic, plasmonic and hybrid structures
    10. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
    11. Nexcelom Bioscience to Distribute FCS Express 4 Cytometry Software with Cellometer Vision CBA Instruments
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/11/2017)... ... ... Personal eye wash is a basic first aid supply for any work environment, but most ... you rinse first if a dangerous substance enters both eyes? It’s one less decision, and ... unique dual eye piece. , “Whether its dirt and debris, or an acid or alkali, ...
    (Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
    (Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
    (Date:10/11/2017)... ... October 11, 2017 , ... A new study published ... frozen and fresh in vitro fertilization (IVF) transfer cycles. The multi-center ... success. , After comparing the results from the fresh and frozen transfer cohorts, ...
    Breaking Biology Technology:
    (Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
    (Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
    (Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
    Breaking Biology News(10 mins):